Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2016-002439-14 | EudraCT Number |
Not provided
Not provided
Not provided
Sponsor decision, unrelated to safety
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with adenoviral conjunctivitis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SHP640 | Experimental | Participants will receive one drop of SHP640 (0.1 percent [%] dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days. |
|
| PVP-I 0.6% | Active Comparator | Participants will receive one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days. |
|
| Placebo | Placebo Comparator | Participants will receive one drop of placebo ophthalmic solution in each eye QID for 7 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SHP640 | Drug | Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Clinical Resolution Among Who Received SHP640 or Placebo on Day 6 | Clinical resolution of adenoviral conjunctivitis was defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her cell culture-immunofluorescence assay (CC-IFA) results at baseline. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). Higher score represent worse symptoms for both scores. Data analysis was performed in SHP640 and placebo reporting groups only but not in PVP-I 0.6%. | Day 6 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Clinical Resolution Among Who Received SHP640 or Povidone-Iodine (PVP-I) on Day 6 | Clinical resolution of adenoviral conjunctivitis was defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). Higher score represent worse symptoms for both scores. Data analysis was performed in SHP640 and PVP-I 0.6% reporting groups only but not in placebo. |
Not provided
Inclusion Criteria:
An understanding, ability, and willingness to fully comply with study procedures and restrictions (by the parent(s), guardian, or legally authorized representative, if applicable).
Ability to voluntarily provide written, signed, and dated (personally or via a parent(s), guardian, or legally authorized representative(s) informed consent (and assent, if applicable) to participate in the study.
Participants of any age at Visit 1 (Note: participants lesser than (<) 3 months of age at Visit 1 must have been full-term, i.e. greater than or equal to (>=) 37 weeks gestational age at birth).
Meet at least 1 of the 2 criteria below:
a) Have a positive AdenoPlus test at Visit 1 in at least 1 eye. b) Have at least 2 of the following 5 criteria, based upon medical history and examination: i.Symptoms within the past 7 days consistent with acute upper respiratory tract infection (eg. sore throat, cough, rhinorrhea, etc).
ii. Contact within the past 7 days with family members or other individuals with recent onset of symptoms consistent with conjunctivitis iii. Acute onset within the past 4 days of one or more of the following ocular symptoms: burning/irritation, foreign body sensation, light sensitivity.
iv. Enlarged periauricular lymph node(s). v. Presence of follicles on tarsal conjunctiva. Note:If the participant only meets Inclusion Criterion (a positive AdenoPlus test in at least 1 eye), then the same eye must meet the mentioned below Inclusion Criterion.
Have a clinical diagnosis of suspected adenoviral conjunctivitis in at least 1 eye confirmed by the presence of the following minimal clinical signs and symptoms in that same eye:
Be willing to discontinue contact lens wear for the duration of the study.
Have a Best Corrected Visual Acuity (BCVA) of 0.60 logMAR or better in each eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. BCVA will be assessed by an age appropriate method in accordance with the AAP Policy Statement for Visual System Assessment in Infants, Children, and Young Adults by Pediatricians (Donahue and Baker 2016; American Academy of Pediatrics 2016).The policy statement recommends formal vision screening can begin at 3 years of age. VA measurements for children under the age of 3 will be done at the discretion of the investigator.
If not done, child should be able to fixate on and follow a moving object, except participants <2 months of age who have not yet developed this ability. Participants <2 months will be enrolled at the discretion of the investigator.
Male, or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol or females of non-childbearing potential.
Exclusion Criteria:
Note:history or concomitant presence of presumed seasonal or perennial allergic conjunctivitis signs/symptoms is not exclusionary.
Neonates or infants (i.e. participants less than 12 months of age) who have suspected or confirmed (based on the result of any test conducted prior to screening) conjunctivitis of gonococcal, chlamydial, herpetic or chemical origin.
Neonates or infants (i.e. participants less than 12 months of age) whose birth mothers had any sexually transmitted disease within 1 month of delivery or any history of genital herpes.
Presence of nasolacrimal duct obstruction at Visit 1 (Day 1).
Presence of any significant ophthalmic condition (e.g. Retinopathy of Prematurity, congenital cataract, congenital glaucoma) or other congenital disorder with ophthalmic involvement that could affect study variables.
Be a known intraocular pressure (IOP) steroid responder, have a known history or current diagnosis of glaucoma, or be a glaucoma suspect.
Have any known clinically significant optic nerve defects.
Have a history of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome; presence of corneal epithelial defect or any significant corneal opacity at Visit 1.
Presence of significant, active condition in the posterior segment which requires invasive treatment (e.g. intravitreal treatment with VEGF inhibitors or corticosteroids) and may progress during the study participation period.
Have used any topical ocular or systemic anti-vials or antibiotics within <= 7 days of enrollment.
Have used any topical ocular Non-steroidal Anti-inflammataory Drugs (NSAIDs) within <= 1 day of enrollment.
Have used any topical ophthalmic steroids in the last <= 14 days.
Have used any systemic corticosteroid agents within <= 14 days of Day 1. Stable (initiated >= 30 days prior to enrollment) use of inhaled and nasal corticosteroids is allowed, given no anticipated change in dose for the duration of the study. Topical dermal steroids are allowed except in the peri-ocular area.
Have used non-corticosteroid immunosuppressive agents within <= 14 days of Day 1.
Have used any topical ophthalmic products, including tear substitutes, and over-the-counter preparations such as lid scrubs, within 2 hours of Visit 1 and be unable to discontinue all topical ophthalmic products for the duration of the study. Use of hot or cold compresses is also not permitted during the study.
Have any significant ocular disease (eg, Sjogren's syndrome) or any uncontrolled systemic disease or debilitating disease (eg, cardiovascular disease, hypertension, sexually transmitted diseases/infections, diabetes or cystic fibrosis), that may affect the study parameters, per the investigator's discretion.
Any known history of immunodeficiency disorder or known active conditions predisposing to immunodeficiency, such as human immunodeficiency virus, hepatitis B or C, evidence of active hepatitis A (antihepatitis A virus immunoglobulin M), or organ or bone marrow transplantation.
Within 30 days prior to the first dose of investigational product:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Study Director | Takeda | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arizona Eye Center | Chandler | Arizona | 85224 | United States | ||
| Midwestern University Eye Institute |
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Not provided
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
A total of 219 participants were randomized and 196 completed the study. Among which 219 were included in intent-to-treat (ITT) population, 217 in safety population, 83 in modified intent-to treat (mITT) population. Two participants were included in ITT population but not in safety population.
This study was conducted at 97 sites in 15 countries between 27 March 2017 (first participant enrolled) to 13 May 2019 (last participant completed).
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | SHP640 | Participants administered one drop of SHP640 (0.1 percent [%] dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days. |
| FG001 | PVP-I 0.6% |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol: Protocol | Jun 30, 2016 | May 8, 2020 |
Not provided
Not provided
Not provided
Not provided
|
| PVP-I 0.6% | Drug | Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days. |
|
| Placebo | Other | Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days. |
|
| Day 6 |
| Number of Participants With Clinical Resolution Among Who Received Povidone-Iodine (PVP-I) or Placebo on Day 6 | Clinical resolution of adenoviral conjunctivitis was defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). Higher score represent worse symptoms for both scores. Data analysis was performed in PVP-I 0.6% and placebo reporting groups only but not in SHP640. | Day 6 |
| Number of Participants With Adenoviral Eradication Among Who Received Povidone-Iodine (PVP-I) or Placebo on Day 3 | Adenoviral eradication for the study eye was defined as negative Cell Culture- Immunofluorescence Assay (CC-IFA) in that eye. CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Data analysis was performed in PVP-I 0.6% and placebo reporting groups only but not in SHP640. | Day 3 |
| Number of Participants With Adenoviral Eradication Among Who Received SHP640 or Placebo on Day 6 | Adenoviral eradication for the study eye was defined as negative CC-IFA in that eye. CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Data analysis was performed in SHP640 and placebo reporting groups only but not in PVP-I 0.6%. | Day 6 |
| Number of Participants With Adenoviral Eradication Among Who Received SHP640 or Povidone-Iodine (PVP-I) on Day 6 | Adenoviral eradication for the study eye was defined as negative CC-IFA in that eye. CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Data analysis was performed in SHP640 and PVP-I 0.6% reporting groups only but not in placebo. | Day 6 |
| Percent Change From Baseline in Adenovirus Viral Titer as Assessed by Quantitative Polymerase Chain Reaction (qPCR) at Day 6 and 8 | qPCR test was performed on all CC-IFA positive samples at all visits to determine viral count in the study eye. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Percent (%) change from baseline in adenovirus viral titer as assessed by qPCR was reported. | Day 6 and 8 |
| Number of Participants With Adenoviral Eradication on Day 8 and 12/Early Termination (ET) | Adenoviral eradication for the study eye was defined as negative CC-IFA in that eye. CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. | Day 8 and 12/ET |
| Number of Participants With Clinical Resolution on on Day 3, 8 and 12/Early Termination (ET) | Clinical resolution of adenoviral conjunctivitis was defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). Higher score represent worse symptoms for both scores. | Day 3, 8 and 12/ET |
| Change From Baseline in Individual Clinical Signs Score at Day 3, 6, 8 and 12/Early Termination (ET) | The Individual clinical signs score (bulbar conjunctival injection and watery conjunctival discharge) in the study were reported. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CCIFA results at baseline. | Day 3, 6, 8 and 12/ET |
| Number of Participants With at Least 2 Point Reduction From Baseline in the Global Clinical Score at Day 3, 6, 8 and 12/Early Termination (ET) | Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. | Day 3, 6, 8 and 12/ET |
| Number of Participants With Modified Clinical Resolution on Day 3, 6, 8 and 12/Early Termination (ET) | Modified clinical resolution was defined as a global clinical score of 0 or 1. Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge. The study eyewas defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. | Day 3, 6, 8 and 12/ET |
| Number of Participants With Expanded Clinical Resolution on Day 3, 6, 8 and 12/Early Termination (ET) | Expanded clinical resolution was defined as a global clinical score of 0, 1, or 2 with neither injection nor discharge having a score of 2. Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. | Day 3, 6, 8 and 12/ET |
| Number of Participants With Status of Cross-over Infection on Day 3, 6, 8 and 12/Early Termination (ET) | Number of participants with status of cross-over infection to a participant's fellow eye. Participants with only 1 infected eye at baseline were reported. | Day 3, 6, 8 and 12/ET |
| Time to Clinical Resolution on Day 3, 6, 8 and 12/Early Termination (ET) | Time to clinical resolution were reported based on the assessments in the study eye. | Day 3, 6, 8 and 12/ET |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Event (SAEs) of SHP640 | An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, is an important medical event. Any AE that occured after the first dose of IP instillation was considered a TEAE. | From start of the study up to Day 14 |
| Glendale |
| Arizona |
| 85308 |
| United States |
| M&M Eye Institute | Prescott | Arizona | 86301 | United States |
| Walman Eye Center | Sun City | Arizona | 85351 | United States |
| Milton M. Hom, OD, FAAO | Azusa | California | 91702 | United States |
| Mark B. Kislinger, MD, PhD, Inc. | Glendora | California | 91741 | United States |
| Inland Eye Specialists | Hemet | California | 92545 | United States |
| Lakeside Vision Center | Irvine | California | 92604 | United States |
| Loma Linda University | Loma Linda | California | 92354 | United States |
| Eye Physicians of Long Beach | Long Beach | California | 90808 | United States |
| Oxford Optical | Los Angeles | California | 90020 | United States |
| Macy Eye Center | Los Angeles | California | 90048 | United States |
| Shultz Chang Vision | Northridge | California | 91325 | United States |
| Stanford Byers Eye Institute | Palo Alto | California | 94303 | United States |
| North Bay Eye Associates, Inc. | Petaluma | California | 94954 | United States |
| Arch Health Partners | Poway | California | 92064 | United States |
| Martel Eye Medical Group | Rancho Cordova | California | 95670 | United States |
| Shasta Eye Medical Group, Inc. | Redding | California | 96002 | United States |
| The Eye Associates | Bradenton | Florida | 34209 | United States |
| South Florida Vision Associates, LLC | Fort Lauderdale | Florida | 33309 | United States |
| Bascom Palmer Eye Institute | Miami | Florida | 33136 | United States |
| Lorites Medical Group | Miami | Florida | 33166 | United States |
| Pediatric & Adult Research Center, LLC | Orlando | Florida | 32825 | United States |
| East Florida Eye Institute | Stuart | Florida | 34494 | United States |
| Andrew Gardner Logan, MD / dba Logan Ophthalmic Research, LLC | Tamarac | Florida | 33321 | United States |
| Eye Care Centers Management, Inc. | Morrow | Georgia | 30260 | United States |
| Jackson Eye | Lake Villa | Illinois | 60046 | United States |
| Illinois Eye Center | Peoria | Illinois | 61615 | United States |
| MediSphere Medical Research Center, an AMR affiliate | Evansville | Indiana | 47714 | United States |
| Kannarr Eye Care | Pittsburg | Kansas | 66762 | United States |
| Koffler Vision Group | Lexington | Kentucky | 40509 | United States |
| Kentucky Eye Institute | Lexington | Kentucky | 40517 | United States |
| Senior Health Services | Louisville | Kentucky | 40220 | United States |
| Baker, Carl W | Paducah | Kentucky | 42001 | United States |
| Lakeview Vision - Gretna | Gretna | Louisiana | 70056 | United States |
| Haik Humble Eye Center | West Monroe | Louisiana | 71291 | United States |
| Eye Center Northeast | Bangor | Maine | 04401 | United States |
| Massachusetts Eye and Ear Infirmary | Boston | Massachusetts | 02114 | United States |
| Shire Call Center | Lexington | Massachusetts | 02421 | United States |
| Clinical Eye Research of Boston | Winchester | Massachusetts | 02114 | United States |
| The Regents of the University of Michigan | Ann Arbor | Michigan | 48105 | United States |
| Minnesota Eye Consultants, P.A. | Bloomington | Minnesota | 55431 | United States |
| Lifelong Vision Foundation | Chesterfield | Missouri | 63017 | United States |
| Moyes Eye Center | Kansas City | Missouri | 64154 | United States |
| Mercy Research | Springfield | Missouri | 65806 | United States |
| Nevada Eye Care Professionals | Las Vegas | Nevada | 89129 | United States |
| Hassman Research Institute | Berlin | New Jersey | 08009 | United States |
| Northern New Jersey Eye Institute | South Orange | New Jersey | 07079 | United States |
| Oculus Research | Raleigh | North Carolina | 27603 | United States |
| James Branch, M.D. | Winston-Salem | North Carolina | 27101 | United States |
| Matossian Eye Associates | Doylestown | Pennsylvania | 18902 | United States |
| UPMC Eye Center | Pittsburgh | Pennsylvania | 15213 | United States |
| Wyomissing Optometric Center | Wyomissing | Pennsylvania | 19610 | United States |
| Black Hills Regional Eye Institute | Rapid City | South Dakota | 59101 | United States |
| The Eye Center at Southern College of Optometry | Memphis | Tennessee | 38104 | United States |
| Total Eye Care, PA | Memphis | Tennessee | 38119 | United States |
| Eye Specialty Group | Memphis | Tennessee | 38120 | United States |
| Nashville Vision Associates | Nashville | Tennessee | 37205 | United States |
| Toyos Clinic | Nashville | Tennessee | 37215 | United States |
| Houston Eye Associates | Houston | Texas | 77025 | United States |
| Lake Travis Eye & Laser Center | Lakeway | Texas | 78734 | United States |
| Houston Eye Associates | League City | Texas | 77573 | United States |
| DCT-Shah Research, LLC dba Discovery Clinical Trials | Mission | Texas | 78572 | United States |
| R and R Eye Research, LLC. | San Antonio | Texas | 78229 | United States |
| Lone Star Eye Care, P.A. | Sugar Land | Texas | 77479 | United States |
| Ericksen Research & Development, LLC | Clinton | Utah | 84015 | United States |
| Emerson Clinical Research Institute, LLC | Falls Church | Virginia | 22046 | United States |
| University of Wisconsin | Madison | Wisconsin | 53705 | United States |
| University of the Sunshine Coast Clinical Trials Centre | Sippy Downs | Queensland | 4556 | Australia |
| Kepler Universitätsklinikum | Linz | 4020 | Austria |
| AKH - Medizinische Universitaet Wien | Vienna | 1090 | Austria |
| Vienna Institute for Research in Ocular Surgery | Vienna | 1140 | Austria |
| The Ottawa Hospital - General Campus, University of Ottawa Eye Institute | Ottawa | Ontario | K1H 8L6 | Canada |
| University of Waterloo School of Optometry and Vision Science | Waterloo | Ontario | N2L 3G1 | Canada |
| McGill University Health Centre/Glen Site / Royal Victoria Hospital | Montreal | Quebec | H4A 3S5 | Canada |
| Eye Clinic Dr Kirsta Turman | Tallinn | 10120 | Estonia |
| East Tallinn Central Hospital | Tallinn | 10138 | Estonia |
| Tartu University Hospital | Tartu | 51010 | Estonia |
| CHU Limoges - Hopital Dupuytren | Limoges | Haute Vienne | 87042 | France |
| Hopital Necker - Enfants Malades | Paris | 75015 | France |
| Klinisches Studienzentrum der Augenklinik | Mainz | 55131 | Germany |
| Augenärzte am Franziskus Hospital | Münster | 48145 | Germany |
| Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont | Szeged | Csongrád megye | 6720 | Hungary |
| Bugat Pal Korhaz | Gyöngyös | Heves County | 3200 | Hungary |
| Debreceni Egyetem | Debrecen | 4032 | Hungary |
| Somogy Megyei Kaposi Mor Oktato Korhaz | Kaposvár | 7400 | Hungary |
| Csolnoky Ferenc Korhaz | Veszprém | 8200 | Hungary |
| L. V. Prasad Eye Institute | Hyderabad | Andhra Pradesh | 500034 | India |
| Sankara Eye Hospital | Bangalore | Karnataka | 560037 | India |
| Bhagwan Mahaveer Jain Hospital | Bangalore | Karnataka | 560052 | India |
| M. S. Ramaiah Medical College and Hospital | Bangalore | Karnataka | 560054 | India |
| Sapthagiri Hospital | Bangalore | Karnataka | 560090 | India |
| K.L.E. Society's Dr. Prabhakar Kore Hospital and Medical Research Centre | Belagavi | Karnataka | 590010 | India |
| NKP Salve Institute of Medical Sciences | Nagpur | Maharashtra | 440025 | India |
| Dr. D. Y. Patil Medical College | Navi Mumbai | Maharashtra | 400706 | India |
| PBMA'S H. V. Desai Eye Hospital | Pune | Maharashtra | 411060 | India |
| S. P. Medical College & Associated Group of Hospitals | Bikaner | Rajasthan | 334003 | India |
| ICARE Eye Hospital and Post Graduate Institute | Noida | Uttar Pradesh | 201301 | India |
| Regional Institute of Ophthalmology | Kolkata | West Bengal | 700073 | India |
| HaEmek Medical Center | Afula | 18341 | Israel |
| Soroka University Medical Center | Beersheba | 84101 | Israel |
| Rambam MC | Haifa | 3109601 | Israel |
| Shaare Zedek Medical Center | Jerusalem | 9103102 | Israel |
| Rabin Medical Center-Beilinson Campus | Petah Tikva | 49100 | Israel |
| Kaplan Medical Center | Rehovot | 76100 | Israel |
| Tel Aviv Sourasky Medical Center | Tel Aviv | 64239 | Israel |
| A.O.U. Policlinico San'Orsola-Malpighi | Bologna | 40138 | Italy |
| Instituto Regional de OftalmologÃa | La Libertad | 13007 | Peru |
| Macula D&T S.R.L. | Lima | 27 | Peru |
| Oftalmosalud SRL. | Lima | 27 | Peru |
| Szpital Specjalistyczny nr 1 | Bytom | 41-902 | Poland |
| Centrum Medyczne UNO-MED | Krakow | 31-070 | Poland |
| Centrum Diagnostyki i Mikrochirurgii Oka LENS | Olsztyn | 10-424 | Poland |
| Centrum Medyczne Uno-Med (Private Practice) | Tarnów | 33-100 | Poland |
| Retina Sp. z o.o. | Warsaw | 01 -364 | Poland |
| Newtown Clinical Research | Johannesburg | Gauteng | 2113 | South Africa |
| Into Research | Pretoria | Gauteng | 0181 | South Africa |
| Pretoria Eye Institute Research Foundation | Pretoria | Gauteng | 83 | South Africa |
| Nelson R Mandela School of Medicine Ophthalmology Department | Durban | KwaZulu-Natal | 4001 | South Africa |
| Instituto Oftalmológico Fernández-Vega | Oviedo | Principality of Asturias | 33012 | Spain |
| Complejo Asistencial Universitario de Burgos | Burgos | 9006 | Spain |
| Hospital Universitari de Girona Dr Josep Trueta | Girona | 17001 | Spain |
| Clinica Oftalmologia Gil Piña | Huelva | 21002 | Spain |
| Clinica Rementeria | Madrid | 28010 | Spain |
| Hospital Universitario Puerta de Hierro Majadahonda | Majadahonda | 28222 | Spain |
| Cartuja Vision | Seville | 41092 | Spain |
| FISABIO-OftalmologÃa Médica | Valencia | 46015 | Spain |
| Hospital Clinico Universitario Lozano Blesa | Zaragoza | 50009 | Spain |
| Hospital Universitario Miguel Servet | Zaragoza | 50009 | Spain |
| Manchester Royal Eye Hospital | Manchester | Greater Manchester | M139WL | United Kingdom |
Participants administered one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days.
| FG002 | Placebo | Participants administered one drop of placebo ophthalmic solution in each eye QID for 7 days. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Intent-To-Treat (ITT) population consisted of all screened participants who were randomized.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | SHP640 | Participants administered one drop of SHP640 (0.1 percent [%] dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days. |
| BG001 | PVP-I 0.6% | Participants administered one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days. |
| BG002 | Placebo | Participants administered one drop of placebo ophthalmic solution in each eye QID for 7 days. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Clinical Resolution Among Who Received SHP640 or Placebo on Day 6 | Clinical resolution of adenoviral conjunctivitis was defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her cell culture-immunofluorescence assay (CC-IFA) results at baseline. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). Higher score represent worse symptoms for both scores. Data analysis was performed in SHP640 and placebo reporting groups only but not in PVP-I 0.6%. | Modified Intent to Treat (mITT) population consisted of a subset of the ITT population who received at least one dose of investigational product (IP) and had a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specified time point. | Posted | Count of Participants | Participants | Day 6 |
|
|
| ||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Clinical Resolution Among Who Received SHP640 or Povidone-Iodine (PVP-I) on Day 6 | Clinical resolution of adenoviral conjunctivitis was defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). Higher score represent worse symptoms for both scores. Data analysis was performed in SHP640 and PVP-I 0.6% reporting groups only but not in placebo. | mITT population consisted of a subset of the ITT population who received at least one dose of IP and had a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specified time point. | Posted | Count of Participants | Participants | Day 6 |
| ||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Clinical Resolution Among Who Received Povidone-Iodine (PVP-I) or Placebo on Day 6 | Clinical resolution of adenoviral conjunctivitis was defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). Higher score represent worse symptoms for both scores. Data analysis was performed in PVP-I 0.6% and placebo reporting groups only but not in SHP640. | mITT population consisted of a subset of the ITT population who received at least one dose of IP and had a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specified time point. | Posted | Count of Participants | Participants | Day 6 |
| ||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Adenoviral Eradication Among Who Received Povidone-Iodine (PVP-I) or Placebo on Day 3 | Adenoviral eradication for the study eye was defined as negative Cell Culture- Immunofluorescence Assay (CC-IFA) in that eye. CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Data analysis was performed in PVP-I 0.6% and placebo reporting groups only but not in SHP640. | mITT population consisted of a subset of the ITT population who received at least one dose of IP and had a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specified time point. | Posted | Count of Participants | Participants | Day 3 |
| ||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Adenoviral Eradication Among Who Received SHP640 or Placebo on Day 6 | Adenoviral eradication for the study eye was defined as negative CC-IFA in that eye. CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Data analysis was performed in SHP640 and placebo reporting groups only but not in PVP-I 0.6%. | mITT population consisted of a subset of the ITT population who received at least one dose of IP and had a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specified time point. | Posted | Count of Participants | Participants | Day 6 |
| ||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Adenoviral Eradication Among Who Received SHP640 or Povidone-Iodine (PVP-I) on Day 6 | Adenoviral eradication for the study eye was defined as negative CC-IFA in that eye. CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Data analysis was performed in SHP640 and PVP-I 0.6% reporting groups only but not in placebo. | mITT population consisted of a subset of the ITT population who received at least one dose of IP and had a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specified time point. | Posted | Count of Participants | Participants | Day 6 |
| ||||||||||||||||||||||||||||||||||
| Secondary | Percent Change From Baseline in Adenovirus Viral Titer as Assessed by Quantitative Polymerase Chain Reaction (qPCR) at Day 6 and 8 | qPCR test was performed on all CC-IFA positive samples at all visits to determine viral count in the study eye. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Percent (%) change from baseline in adenovirus viral titer as assessed by qPCR was reported. | The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed. | Posted | Day 6 and 8 |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Adenoviral Eradication on Day 8 and 12/Early Termination (ET) | Adenoviral eradication for the study eye was defined as negative CC-IFA in that eye. CC-IFA for each eye was conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. | mITT population consisted of a subset of the ITT population who received at least one dose of IP and had a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specific categories. | Posted | Count of Participants | Participants | Day 8 and 12/ET |
| ||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Clinical Resolution on on Day 3, 8 and 12/Early Termination (ET) | Clinical resolution of adenoviral conjunctivitis was defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. The study eye was defined based on participant's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity of watery discharge observed in the lower conjunctival fornix and in the lower lid margin). Higher score represent worse symptoms for both scores. | mITT population consisted of a subset of the ITT population who received at least one dose of IP and had a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specific categories. | Posted | Count of Participants | Participants | Day 3, 8 and 12/ET |
| ||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Individual Clinical Signs Score at Day 3, 6, 8 and 12/Early Termination (ET) | The Individual clinical signs score (bulbar conjunctival injection and watery conjunctival discharge) in the study were reported. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CCIFA results at baseline. | The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed. | Posted | Day 3, 6, 8 and 12/ET |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With at Least 2 Point Reduction From Baseline in the Global Clinical Score at Day 3, 6, 8 and 12/Early Termination (ET) | Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. | mITT population consisted of a subset of the ITT population who received at least one dose of IP and had a positive CC-IFA adenovirus test at baseline in the study eye. Here, the number of participants analyzed refer to the participants evaluable for this outcome at specific categories. | Posted | Count of Participants | Participants | Day 3, 6, 8 and 12/ET |
| ||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Modified Clinical Resolution on Day 3, 6, 8 and 12/Early Termination (ET) | Modified clinical resolution was defined as a global clinical score of 0 or 1. Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge. The study eyewas defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. | The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed. | Posted | Day 3, 6, 8 and 12/ET |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Expanded Clinical Resolution on Day 3, 6, 8 and 12/Early Termination (ET) | Expanded clinical resolution was defined as a global clinical score of 0, 1, or 2 with neither injection nor discharge having a score of 2. Global clinical score was the sum of bulbar conjunctival injection and watery conjunctival discharge. The study eye was defined based on participants bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. | The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed. | Posted | Day 3, 6, 8 and 12/ET |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Status of Cross-over Infection on Day 3, 6, 8 and 12/Early Termination (ET) | Number of participants with status of cross-over infection to a participant's fellow eye. Participants with only 1 infected eye at baseline were reported. | The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed. | Posted | Day 3, 6, 8 and 12/ET |
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Time to Clinical Resolution on Day 3, 6, 8 and 12/Early Termination (ET) | Time to clinical resolution were reported based on the assessments in the study eye. | The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety. Hence, for this outcome measure, the planned data collection and analysis was not performed. | Posted | Day 3, 6, 8 and 12/ET |
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Event (SAEs) of SHP640 | An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, is an important medical event. Any AE that occured after the first dose of IP instillation was considered a TEAE. | Safety Population consisted of all participants who received at least one dose of IP. | Posted | Count of Participants | Participants | From start of the study up to Day 14 |
|
From start of the study up to Day 14
Safety Population consisted of all participants who received at least one dose of IP.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | SHP640 | Participants received one drop of SHP640 (0.1 percent [%] dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days. | 0 | 86 | 0 | 86 | 12 | 86 |
| EG001 | PVP-I 0.6% | Participants received one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days. | 0 | 90 | 1 | 90 | 8 | 90 |
| EG002 | Placebo | Participants received one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days. | 0 | 41 | 0 | 41 | 1 | 41 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pneumonia bacterial | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Instillation site pain | General disorders | MedDRA 19.1 | Non-systematic Assessment |
|
The study was terminated as the sponsor discontinued the SHP640 clinical development with reason unrelated to safety.
If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Shire | +1 866 842 5335 | ClinicalTransparency@shire.com |
| Prot_000.pdf |
| Prot | Yes | No | No | Study Protocol: Amendment 1 | Nov 28, 2016 | May 8, 2020 | Prot_001.pdf |
| Prot | Yes | No | No | Study Protocol: Amendment 2 | Feb 15, 2017 | May 8, 2020 | Prot_002.pdf |
| Prot | Yes | No | No | Study Protocol: Amendment 3 | Dec 13, 2017 | May 8, 2020 | Prot_003.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jun 24, 2019 | May 8, 2020 | SAP_004.pdf |
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| PVP-I 0.6% |
Participants administered one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days. |
| OG002 | Placebo | Participants administered one drop of placebo ophthalmic solution in each eye QID for 7 days. |
|
|
| PVP-I 0.6% |
Participants administered one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days. |
| OG002 | Placebo | Participants administered one drop of placebo ophthalmic solution in each eye QID for 7 days. |
|
|
| Placebo |
Participants administered one drop of placebo ophthalmic solution in each eye QID for 7 days. |
|
|
Participants administered one drop of placebo ophthalmic solution in each eye QID for 7 days. |
|
|
Participants administered one drop of placebo ophthalmic solution in each eye QID for 7 days. |
|
|
|
|
|
Participants administered one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days.
| OG002 | Placebo | Participants administered one drop of placebo ophthalmic solution in each eye QID for 7 days. |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Participants |
|
|
Participants administered one drop of placebo ophthalmic solution in each eye QID for 7 days. |
|
|